<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Support Care Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Support Care Cancer</journal-id><journal-title-group><journal-title>Supportive Care in Cancer</journal-title></journal-title-group><issn pub-type="ppub">0941-4355</issn><issn pub-type="epub">1433-7339</issn><publisher><publisher-name>Springer Berlin Heidelberg</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25218610</article-id><article-id pub-id-type="pmc">4311064</article-id><article-id pub-id-type="publisher-id">2435</article-id><article-id pub-id-type="doi">10.1007/s00520-014-2435-5</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Long-term safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate-to-severe chronic cancer pain</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ahmedzai</surname><given-names>Sam H.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Leppert</surname><given-names>Wojciech</given-names></name><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Janecki</surname><given-names>Marcin</given-names></name><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Pakosz</surname><given-names>Artur</given-names></name><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Lomax</surname><given-names>Mark</given-names></name><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author"><name><surname>Duerr</surname><given-names>Heike</given-names></name><xref ref-type="aff" rid="Aff6"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Hopp</surname><given-names>Michael</given-names></name><address><email>michael.hopp@mundipharma-rd.eu</email></address><xref ref-type="aff" rid="Aff6"/></contrib><aff id="Aff1"><label/>Academic Unit of Supportive Care, School of Medicine and Biomedical Sciences, University of Sheffield, Sheffield, UK </aff><aff id="Aff2"><label/>Chair and Department of Palliative Medicine, Poznan University of Medical Sciences, Poznan, Poland </aff><aff id="Aff3"><label/>Department of Palliative Care and Palliative Medicine, Medical University of Silesian, Katowice, Poland </aff><aff id="Aff4"><label/>God&#x02019;s Mercy Hospice, Gliwice, Poland </aff><aff id="Aff5"><label/>Mundipharma Research Limited, Cambridge, UK </aff><aff id="Aff6"><label/>Mundipharma Research GmbH &#x00026; Co. KG, Limburg, Germany </aff></contrib-group><pub-date pub-type="epub"><day>14</day><month>9</month><year>2014</year></pub-date><pub-date pub-type="pmc-release"><day>14</day><month>9</month><year>2014</year></pub-date><pub-date pub-type="ppub"><year>2015</year></pub-date><volume>23</volume><fpage>823</fpage><lpage>830</lpage><history><date date-type="received"><day>9</day><month>5</month><year>2014</year></date><date date-type="accepted"><day>2</day><month>9</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2014</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.</license-p></license></permissions><abstract id="Abs1"><sec><title>Aim</title><p>To evaluate the long-term safety and efficacy of prolonged-release oxycodone/naloxone (OXN PR) and its impact on quality of life (QoL), in patients with moderate-to-severe cancer pain.</p></sec><sec><title>Methods</title><p>This was an open-label extension (OLE) of a 4&#x000a0;week, randomized, double-blind (DB) study in which patients with moderate-to-severe cancer pain had been randomized to OXN PR or oxycodone PR (OxyPR). During the OLE phase, patients were treated with OXN PR capsules (&#x02264;20/60&#x000a0;mg/day) for &#x02264;24&#x000a0;weeks. Outcome measures included safety, efficacy and QoL.</p></sec><sec><title>Results</title><p>One hundred and twenty-eight patients entered the OLE, average pain scores based on the modified Brief Pain Inventory&#x02014;Short Form were low and stable over the 24-week period. The improvement in bowel function and constipation symptoms as measured by the Bowel Function Index and patient assessment of constipation in patients treated with OXN PR during the 4-week DB study was maintained. In patients treated with OxyPR during the DB phase, bowel function and constipation symptoms were improved during the OLE. In the DB and in the OLE, health status and QoL were similar for patients treated with OXN PR and OxyPR. There were no unexpected safety or tolerability issues.</p></sec><sec><title>Conclusions</title><p>In patients with moderate-to-severe cancer pain, long-term use of OXN PR is well tolerated and effective, resulting in sustained analgesia, improved bowel function and improved symptoms of constipation.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Oxycodone</kwd><kwd>Naloxone</kwd><kwd>Opioid-induced constipation</kwd><kwd>Analgesia</kwd><kwd>Bowel function</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag Berlin Heidelberg 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p>Pain is a common and debilitating symptom of cancer and can significantly impact the lives of patients through detrimental effects on physical functioning, psychological well-being and social interactions [<xref ref-type="bibr" rid="CR1">1</xref>]. Pain affects a large proportion of cancer patients, with prevalence rates ranging from 33&#x000a0;% in patients after curative treatment to 64&#x000a0;% in patients with advanced, metastatic or terminal phase disease [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. In a 2009 European survey, 56&#x000a0;% of cancer patients were demonstrated to suffer pain several times per month, with over 90&#x000a0;% of these reporting their pain as moderate to severe in intensity [<xref ref-type="bibr" rid="CR4">4</xref>].</p><p>Opioid analgesics are the established treatment for the relief of moderate-to-severe cancer pain and several different opioids are now available [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. For years, morphine has been the accepted gold standard for the treatment of cancer pain and is endorsed by the European Association of Palliative Care [<xref ref-type="bibr" rid="CR6">6</xref>]. Oxycodone (a semi-synthetic opioid analgesic) has proven efficacy in the management of severe pain of different aetiologies [<xref ref-type="bibr" rid="CR7">7</xref>&#x02013;<xref ref-type="bibr" rid="CR10">10</xref>]. A series of systematic reviews on the use of opioids in cancer patients found that oxycodone and hydromorphone have efficacy and tolerability profiles comparable with that of morphine [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>].</p><p>Although opioids have proven analgesic efficacy, their use is frequently complicated by a range of side effects, which include nausea, sedation, euphoria/dysphoria, constipation and itching [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. The most common and often most debilitating side effect is opioid-induced bowel dysfunction (OIBD), which comprises a constellation of gastrointestinal (GI) adverse events (AEs) including constipation, hard dry stools, straining, incomplete evacuation, bloating, abdominal cramping, abdominal distension and increased gastric reflux [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. The primary symptom of OIBD is constipation, which occurs in approximately 90&#x000a0;% of cancer patients receiving opioid therapy and persists over time [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. Current strategies to manage OIBD are non-specific and frequently ineffective [<xref ref-type="bibr" rid="CR18">18</xref>]. Increasing dietary fibre, fluid intake and physical mobility are usually insufficient to prevent or treat OIBD and the majority of patients receiving long-term opioid therapy require laxatives [<xref ref-type="bibr" rid="CR13">13</xref>]. Laxatives do not address the underlying opioid receptor-mediated cause of constipation and evidence for their effectiveness is weak; therefore, OIC persists in many patients [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR19">19</xref>].</p><p>A novel therapeutic approach to bypass the GI effects of opioids involves co-administration of an opioid antagonist (naloxone). When administered orally in a prolonged-release (PR) formulation, naloxone has a low systemic bioavailability (&#x0003c;3&#x000a0;%) and antagonises peripheral opioid receptors in the GI tract with little impact on centrally-acting opioid analgesia [<xref ref-type="bibr" rid="CR20">20</xref>&#x02013;<xref ref-type="bibr" rid="CR22">22</xref>]. Oral naloxone can, therefore, improve OIC [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. In patients with moderate-to-severe non-cancer pain, randomized phase III trials have demonstrated that co-administration of prolonged-release (PR) oxycodone with naloxone (OXN PR) provides effective analgesia whilst significantly reducing the impact of OIBD and OIC compared with oxycodone PR alone (OxyPR) [<xref ref-type="bibr" rid="CR25">25</xref>&#x02013;<xref ref-type="bibr" rid="CR27">27</xref>] and that this effect is maintained over the long term (&#x02264;52&#x000a0;weeks) [<xref ref-type="bibr" rid="CR28">28</xref>]. Similar safety and efficacy has been demonstrated in a randomized phase II study of OxyPR vs OXN PR in patients with moderate-to-severe cancer pain [<xref ref-type="bibr" rid="CR29">29</xref>]; although, the long-term effects on this patient population has not yet been demonstrated. Here, we report results of a long-term open-label extension (OLE) of the phase II study in which patients were maintained on or switched to OXN PR.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Methods</title><sec id="Sec3"><title>Study design</title><p>This was a 24&#x000a0;week, uncontrolled, open-label extension of a 4&#x000a0;week, randomized, double-blind study (OXN2001S; NCT00513656) [<xref ref-type="bibr" rid="CR29">29</xref>] conducted to evaluate the long-term safety and efficacy of OXN PR vs OxyPR in patients with moderate-to-severe cancer pain. The study was performed in compliance with good clinical practice and in accordance with the Declaration of Helsinki.</p></sec><sec id="Sec4"><title>Inclusion and exclusion criteria</title><p>Patients completing the double-blind period and those who had discontinued prematurely due to constipation were eligible to enter the OLE phase. Patients aged &#x02265;18&#x000a0;years were enrolled into the double-blind phase of the study if they had moderate-to-severe chronic cancer pain that required &#x02018;round-the-clock&#x02019; opioid therapy and constipation secondary to opioid therapy [<xref ref-type="bibr" rid="CR29">29</xref>].</p></sec><sec id="Sec5"><title>Study treatment</title><p>During the double-blind phase, participants were randomized to OXN PR or OxyPR for 4&#x000a0;weeks (&#x02264;120&#x000a0;mg/day). During the OLE, all patients received OXN PR every 12&#x000a0;h for &#x02264;24&#x000a0;weeks). Study Visit 9a (Day 1) was the first visit of the OLE phase of the study and typically occurred on the same day as Visit 9 (end of the double-blind phase) (Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1A</xref>).<fig id="Fig1"><label>Fig 1</label><caption><p>Study design (<bold>A</bold>) and patient disposition (<bold>B</bold>). <italic>AEs</italic> adverse events, <italic>n</italic> number of patients; <italic>OLE</italic> open-label extension, <italic>OXN PR</italic> prolonged-release oxycodone/naloxone tablets, <italic>OxyPR</italic> prolonged-release oxycodone tablets, <italic>R</italic> randomization, <italic>V</italic> visit, <italic>WK</italic> week. <italic>Superscript letter a</italic> indicates day or week since the beginning of the open-label extension phase; V9a was the first visit of the open-label extension phase and typically occurred on the same day as visit 9 (end of double-blind phase). <italic>Superscript letter b</italic> includes two patients who discontinued from the double-blind phase due to constipation and entered the OLE phase</p></caption><graphic xlink:href="520_2014_2435_Fig1_HTML" id="MO1"/></fig></p><p>The initial starting dose was the effective analgesic dose based on oxycodone or OXN PR that the patient was on at the end of the double-blind phase. Any patient on a dose of &#x02264;80&#x000a0;mg/day OxyPR was switched directly to OXN PR. For example, all patients on 80&#x000a0;mg/day OxyPR started with a daily dose of OXN PR 80/40&#x000a0;mg. Those patients on &#x0003e;80&#x000a0;mg/day OxyPR were switched to OXN PR in a stepwise manner. All patients receiving 90, 100, 110, or 120&#x000a0;mg/day OxyPR were started on OXN PR 40/20&#x000a0;mg 12&#x000a0;hourly with the remainder of their oxycodone dose given as OxyPR. Dose titration was permitted at the discretion of the investigator to &#x02264;120/60&#x000a0;mg/day. A total of 19 patients received OXN PR at a daily dose of &#x0003e;80/40&#x000a0;mg; safety findings for these patients were no different from the whole population.</p><p>Rescue medications (Oxy IR 5&#x000a0;mg and laxative bisacodyl 5&#x000a0;mg) were supplied for the first 7&#x000a0;days of the study. After 7&#x000a0;days, laxative use was documented as concomitant medication.</p></sec><sec id="Sec6"><title>Study assessments</title><p>Efficacy was evaluated based on the following measurements: Brief Pain Inventory&#x02014;Short Form (BPI-SF), a patient-rated scale based on &#x02018;least&#x02019;, &#x02018;average&#x02019; and &#x02018;worst&#x02019; pain felt over the previous week [<xref ref-type="bibr" rid="CR30">30</xref>]; Bowel Function Index (BFI) <sup>a</sup> comprising three components (ease of defecation, feeling of incomplete bowel evacuations and personal judgement of constipation) [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]; patient assessment of constipation (PAC-SYM) [<xref ref-type="bibr" rid="CR33">33</xref>]; rescue medications (Oxy IR and laxative); number of bowel movements; health status (EuroQol EQ-5D) and quality of life (QoL) (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30; EORTC QLQ-C30) [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. Safety assessments included adverse events (AEs) and serious AEs, physical and laboratory evaluations, 12-lead electrocardiograph, and evaluation of the symptoms of opiate withdrawal as measured by the Subjective Opiate Withdrawal Scale (SOWS) collected 1&#x000a0;day and 1&#x000a0;week following the start of the OLE [<xref ref-type="bibr" rid="CR36">36</xref>].</p><p><sup>a</sup>Copyright for the BFI is owned by Mundipharma Laboratories GmbH, Switzerland, 2002; the BFI is subject of European Patent Application Publication No. EP 1,860,988 and corresponding patents and applications in other countries.</p></sec><sec id="Sec7"><title>Statistical analysis</title><p>All analyses were performed on the OLE safety population (patients who received at least one dose of study medication during the OLE. All efficacy and safety variables were summarized descriptively. All continuous variables were summarized using the following descriptive statistics: n, mean, standard deviation (SD), median, minimum and maximum. The frequency and percentage of observed levels were reported for all categorical measures.</p></sec></sec><sec id="Sec8" sec-type="results"><title>Results</title><sec id="Sec9"><title>Patient characteristics</title><p>A total of 128 patients entered the OLE phase of which 126 (98.4&#x000a0;%) had previously completed the double-blind phase and 2 (1.6&#x000a0;%) had discontinued due to constipation. All 128 patients in the OLE phase received study medication and 68 patients (53.1&#x000a0;%) completed the study. Fifty-three per cent and 56.9&#x000a0;% of patients were male and female, respectively, and the mean age was 62.5&#x000a0;years. The most common cancers were breast (19.5&#x000a0;%), lung (8.6&#x000a0;%) and prostate (11.7&#x000a0;%) (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Patient demographics and clinical characteristics (safety population)</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Characteristic</th><th>OXN PR (<italic>N</italic>&#x02009;=&#x02009;128)</th></tr></thead><tbody><tr><td>Mean age, years (SD)</td><td char="(" align="char">62.5 (10.3)</td></tr><tr><td>Age &#x02264;65&#x000a0;years, <italic>n</italic> (%)</td><td char="(" align="char">74 (57.8)</td></tr><tr><td>Male, <italic>n</italic> (%)</td><td char="(" align="char">68 (53.1)</td></tr><tr><td colspan="2">Race, <italic>n</italic> (%)</td></tr><tr><td>&#x02003;Caucasian</td><td char="(" align="char">127 (99.2)</td></tr><tr><td>&#x02003;Black</td><td char="(" align="char">1 (0.8)</td></tr><tr><td>BMI, kg/m<sup>2</sup>
</td><td char="(" align="char">(<italic>n</italic>&#x02009;=&#x02009;123)</td></tr><tr><td>&#x02003;Mean (SD)</td><td char="(" align="char">25.3 (5.1)</td></tr><tr><td>&#x02003;Median (range)</td><td char="(" align="char">25.1 (16&#x02013;40)</td></tr></tbody></table><table-wrap-foot><p>
<italic>BMI</italic> body mass index, <italic>OXN PR</italic> prolonged-release oxycodone/naloxone tablets, <italic>SD</italic> standard deviation</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec10"><title>Efficacy</title><sec id="Sec11"><title>OXN PR dose</title><p>Mean duration of exposure to OXN PR was 122.2&#x000a0;days and the mean daily dose was 56.2&#x000a0;mg. The majority of subjects (69.5&#x000a0;%) remained on their starting dose for the duration of the study. Thirty-four subjects progressed to a slightly higher dose (usually 10 or 20&#x000a0;mg or higher) by the end of the study/discontinuation.</p></sec><sec id="Sec12"><title>Pain (BPI-SF)</title><p>At the end of the double-blind phase of the study in which patients were treated with OxyPR or OXN PR, there was no significant difference in pain control (as assessed by the BPI-SF) between the two treatments [<xref ref-type="bibr" rid="CR29">29</xref>]. At the beginning of the OLE, BPI-SF pain scores for &#x02018;average pain&#x02019; were low in both groups: mean (SD) 3.42 (2.03) and 3.63 (1.76) for OXN PR and OxyPR, respectively. BPI-SF scores remained consistently low and stable in both groups over the OLE period with scores of 3.71 (2.12) for OxyPR and 3.56 (2.27) for OXN PR at Week 24 (Figure&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig2"><label>Fig 2</label><caption><p>BPI-SF average pain scores (LOCF) by study visit (OLE safety population). <italic>BPI-SF</italic> Brief Pain Inventory-Short Form, <italic>LOCF</italic> last observation carried forward, <italic>OLE</italic> open-label extension, <italic>OXN PR</italic> prolonged-release oxycodone/naloxone tablets, <italic>OxyPR</italic> prolonged-release oxycodone tablets, <italic>SD</italic> standard deviation. <italic>Superscript letter a</italic> indicates day or week since the beginning of the open-label extension phase. Data for the DB period are based on the per protocol population (LOCF): <italic>OXN PR</italic>, <italic>n</italic>&#x02009;=&#x02009;62 OxyPR, <italic>n</italic>&#x02009;=&#x02009;71; higher scores indicate more severe pain (<italic>0</italic> no pain, <italic>10</italic> most severe pain)</p></caption><graphic xlink:href="520_2014_2435_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec13"><title>Bowel function index</title><p>At the end of the double-blind phase, OXN PR is both statistically significantly superior in respect to BFI and has also demonstrated a change that is clinically relevant compared with OxyPR [<xref ref-type="bibr" rid="CR29">29</xref>]. For patients that received OXN PR during the DB phase (OLE baseline score [SD]: 38.08 [26.94]), the improvement in BFI was maintained during the OLE (mean BFI: 37.90 [28.06] at Week 12 and 39.02 [27.70] at Week 24). For patients treated with OxyPR during the DB phase (OLE baseline score: 46.61 [26.84]), mean BFI scores were reduced to 38.52 (27.69) at Week 12 and 38.78 (27.45) at Week 24, comparable to those who had previously received OXN PR (Figure&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>).<fig id="Fig3"><label>Fig 3</label><caption><p>BFI scores (LOCF) by study visit (OLE safety population). <italic>BFI</italic> bowel function index, <italic>LOCF</italic> last observation carried forward, <italic>OLE</italic> open-label extension, <italic>OXN PR</italic> prolonged-release oxycodone/naloxone tablets, <italic>OxyPR</italic> prolonged-release oxycodone tablets, <italic>SD</italic> standard deviation. <italic>Superscript letter a</italic> indicates day or week since the beginning of the open-label extension phase. Data for the DB period are based on the full analysis population (LOCF); <italic>OXN PR</italic>, <italic>n</italic>&#x02009;=&#x02009;77; OxyPR, <italic>n</italic>&#x02009;=&#x02009;80; higher scores indicate more severe constipation</p></caption><graphic xlink:href="520_2014_2435_Fig3_HTML" id="MO3"/></fig></p></sec><sec id="Sec14"><title>Constipation symptoms (PAC-SYM)</title><p>At the end of the double-blind phase, a statistically significantly greater improvement in constipation symptoms was observed for OXN PR compared with OxyPR [<xref ref-type="bibr" rid="CR29">29</xref>]. At the beginning of the OLE phase, mean (SD) PAC-SYM total symptoms scores were 10.55 (8.60) and 15.53 (10.20) for OXN PR and OxyPR, respectively. The improvement in constipation symptoms seen in the OXN PR group was maintained during the OLE, with a mean PAC-SYM (SD) of 12.14 (9.65) at Week 24. For patients who had received OxyPR during the double-blind period, mean PAC-SYM scores were reduced to 12.81 (10.10) at Week 24 (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Patient assessment of constipation using PAC-SYM (OLE safety population)</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th colspan="2">Treatment during the DB phase</th><th rowspan="2">All OLE patients (<italic>N</italic>&#x02009;=&#x02009;128)</th></tr><tr><th>OxyPR (<italic>n</italic>&#x02009;=&#x02009;62)</th><th>OXN PR (<italic>n</italic>&#x02009;=&#x02009;66)</th></tr></thead><tbody><tr><td colspan="4">Total symptom score</td></tr><tr><td colspan="4">&#x02003;Day 1</td></tr><tr><td>&#x02003;&#x02003;
<italic>n</italic>
</td><td char="(" align="char">62</td><td char="(" align="char">66</td><td char="(" align="char">128</td></tr><tr><td>&#x02003;&#x02003;Mean (SD)</td><td char="(" align="char">15.53 (10.20)</td><td char="(" align="char">10.55 (8.60)</td><td char="(" align="char">12.96 (9.70)</td></tr><tr><td colspan="4">&#x02003;Week 12</td></tr><tr><td>&#x02003;&#x02003;
<italic>n</italic>
</td><td char="(" align="char">41</td><td char="(" align="char">43</td><td char="(" align="char">84</td></tr><tr><td>&#x02003;&#x02003;Mean (SD)</td><td char="(" align="char">13.22 (11.83)</td><td char="(" align="char">9.67 (7.43)</td><td char="(" align="char">11.40 (9.93)</td></tr><tr><td colspan="4">&#x02003;Week 24</td></tr><tr><td>&#x02003;&#x02003;
<italic>n</italic>
</td><td char="(" align="char">52</td><td char="(" align="char">44</td><td char="(" align="char">96</td></tr><tr><td>&#x02003;&#x02003;Mean (SD)</td><td char="(" align="char">12.81 (10.10)</td><td char="(" align="char">11.34 (9.14)</td><td char="(" align="char">12.14 (9.65)</td></tr><tr><td colspan="4">Frequency of symptoms</td></tr><tr><td colspan="4">&#x02003;Day 1</td></tr><tr><td>&#x02003;&#x02003;
<italic>n</italic>
</td><td char="(" align="char">61</td><td char="(" align="char">66</td><td char="(" align="char">127</td></tr><tr><td>&#x02003;&#x02003;Mean (SD)</td><td char="(" align="char">1.93 (1.31)</td><td char="(" align="char">1.44 (1.07)</td><td char="(" align="char">1.68 (1.21)</td></tr><tr><td colspan="4">&#x02003;Week 12</td></tr><tr><td>&#x02003;&#x02003;
<italic>n</italic>
</td><td char="(" align="char">41</td><td char="(" align="char">43</td><td char="(" align="char">84</td></tr><tr><td>&#x02003;&#x02003;Mean (SD)</td><td char="(" align="char">1.63 (1.39)</td><td char="(" align="char">1.30 (1.06)</td><td char="(" align="char">1.46 (1.24)</td></tr><tr><td colspan="4">&#x02003;Week 24</td></tr><tr><td>&#x02003;&#x02003;
<italic>n</italic>
</td><td char="(" align="char">51</td><td char="(" align="char">43</td><td char="(" align="char">94</td></tr><tr><td>&#x02003;&#x02003;Mean (SD)</td><td char="(" align="char">1.67 (1.34)</td><td char="(" align="char">1.77 (1.27)</td><td char="(" align="char">1.71 (1.30)</td></tr></tbody></table><table-wrap-foot><p>Higher symptom scores and higher frequency of symptoms indicate more severe constipation</p><p>
<italic>OLE</italic> open-label extension, <italic>PAC-SYM</italic> Patient Assessment of Constipation Symptoms, <italic>SD</italic> standard deviation</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec15"><title>Rescue medication</title><p>During the first 7&#x000a0;days of the OLE, the need for rescue medication was low. A total of 37.5&#x000a0;% of patients used laxatives. The mean bisacodyl dose in 7&#x000a0;days was 6.09&#x000a0;mg, which translates to approximately one tablet used in 7&#x000a0;days. A mean of 1.1 (range: 0&#x02013;3.9) capsules of Oxy IR 5&#x000a0;mg were required for rescue analgesia per day.</p></sec><sec id="Sec16"><title>QoL</title><p>In the double-blind phase of the study, health status and QoL were similar between OXN PR and OxyPR groups [<xref ref-type="bibr" rid="CR29">29</xref>]. These results were maintained during the OLE. In the total OLE population, the mean (SD) EQ-5D index score was 0.49 (0.31) at day 1, 0.59 (0.25) at week 12 and 0.46 (0.38) at week 24. The EORTC QLQ-C30 global health status scores were 45.83 (20.36) at day 1, 53.08 (20.07) at week 12 and 43.06 (23.90) at week 24. For the specific EORTC constipation scale, the score was at least maintained and suggested an improvement over the OLE with mean (SD) scores in the total OLE population of 45.31 (35.18) at day 1, 38.49 (35.66) at week 12 and 42.71 (34.44) at week 24.</p></sec></sec><sec id="Sec17"><title>Safety</title><p>Overall, 93.8&#x000a0;% of patients experienced at least one AE in the OLE phase of which 28.1&#x000a0;% were classed as having AEs related to study treatment according to investigators. Fifty-nine patients (46.1&#x000a0;%) experienced serious adverse events (SAEs). A total of four SAEs in four patients were related to study treatment: constipation, dyspnoea, paralytic ileus and worsening of cancer-related pain. Two additional SAEs in one patient were assessed as treatment-related by the sponsor. A total of 38 patients discontinued during the OLE. In total, 28 patients (21.9&#x000a0;%) died during the study. Twenty-four of these deaths were due to disease progression or events related to disease progression; the other deaths were due to sepsis, worsening dyspnoea, lung embolism and cardiac arrest. The death from worsening of dyspnoea was recorded as unlikely to be related to study medication. All other deaths were recorded as unrelated to study medication. There were no clinically important changes in vital signs, laboratory values and electrocardiographs<italic>.</italic> Mean (SD) SOWS scores in the OLE safety population were comparable with those collected in the respective double-blind phase and decreased from 7.90 (7.39) at day 1 to 7.36 (6.24) at week 1 of the OLE. SOWS scores were comparable in both patient groups of the double-blind phase (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).<table-wrap id="Tab3"><label>Table 3</label><caption><p>Summary of adverse events (OLE safety population)</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Oxycodone/naloxone<break/>Number of patients with events, <italic>n</italic> (%)<break/>(<italic>N</italic>&#x02009;=&#x02009;128)</th></tr></thead><tbody><tr><td>Total AE</td><td char="(" align="char">120 (93.8)</td></tr><tr><td>AEs related to study medication</td><td char="(" align="char">36 (28.1)</td></tr><tr><td>Discontinuations due to AE</td><td char="(" align="char">38 (29.7)</td></tr><tr><td>SAE</td><td char="(" align="char">59 (46.1)</td></tr><tr><td>SAEs related to study medication</td><td char="(" align="char">4 (3.1)</td></tr><tr><td>Blood and lymphatic system disorders</td><td char="(" align="char">17 (13.3)</td></tr><tr><td>&#x02003;Anaemia</td><td char="(" align="char">8 (6.3)</td></tr><tr><td>Gastrointestinal disorders</td><td char="(" align="char">44 (34.4)</td></tr><tr><td>&#x02003;Abdominal pain</td><td char="(" align="char">7 (5.5)</td></tr><tr><td>&#x02003;Constipation</td><td char="(" align="char">13 (10.2)</td></tr><tr><td>&#x02003;Diarrhoea</td><td char="(" align="char">7 (5.5)</td></tr><tr><td>&#x02003;Nausea</td><td char="(" align="char">18 (14.1)</td></tr><tr><td>&#x02003;Vomiting</td><td char="(" align="char">8 (6.3)</td></tr><tr><td>General disorders and administration site conditions</td><td char="(" align="char">46 (35.9)</td></tr><tr><td>&#x02003;Asthenia</td><td char="(" align="char">8 (6.3)</td></tr><tr><td>&#x02003;Peripheral oedema</td><td char="(" align="char">17 (13.3)</td></tr><tr><td>&#x02003;Pain</td><td char="(" align="char">11 (8.6)</td></tr><tr><td>&#x02003;Pyrexia</td><td char="(" align="char">7 (5.5)</td></tr><tr><td>Investigations</td><td char="(" align="char">49 (38.3)</td></tr><tr><td>&#x02003;Increased blood uric acid</td><td char="(" align="char">7 (5.5)</td></tr><tr><td>&#x02003;Increased gamma-glutamyl transferase</td><td char="(" align="char">7 (5.5)</td></tr><tr><td>&#x02003;Decrease haemoglobin</td><td char="(" align="char">15 (11.7)</td></tr><tr><td>&#x02003;Decreased lymphocyte count</td><td char="(" align="char">10 (7.8)</td></tr><tr><td>Metabolism and nutrition disorders</td><td char="(" align="char">26 (20.3)</td></tr><tr><td>&#x02003;Anorexia</td><td char="(" align="char">11 (8.6)</td></tr><tr><td>Neoplasms benign, malignant and unspecified (including cysts and polyps)</td><td char="(" align="char">51 (39.8)</td></tr><tr><td>&#x02003;Cancer pain</td><td char="(" align="char">22 (17.2)</td></tr><tr><td>&#x02003;Malignant neoplasm progression</td><td char="(" align="char">32 (25.0)</td></tr></tbody></table><table-wrap-foot><p>
<italic>AE</italic> adverse event, <italic>OLE</italic> open-label extension, <italic>SAE</italic> serious adverse event</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec18" sec-type="discussion"><title>Discussion</title><p>Pain is a common symptom of cancer, and if poorly treated, can adversely affect patients&#x02019; physical functioning, psychological well-being and social interactions [<xref ref-type="bibr" rid="CR4">4</xref>]. Whilst opioids are widely recommended to relieve pain in cancer patients [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR37">37</xref>], successful management requires that the benefits of these agents outweigh the impact of treatment-related side effects [<xref ref-type="bibr" rid="CR38">38</xref>]. Opioid-induced bowel dysfunction, particularly OIC, is the most frequently reported AE experienced by patients receiving long-term opioid therapy and can be sufficiently severe to undermine the effectiveness of pain management [<xref ref-type="bibr" rid="CR13">13</xref>].</p><p>To our knowledge, this OLE study is the largest trial to date evaluating OIC in cancer pain and provides a sound basis for evaluation of long-term safety and efficacy data. Results from this study demonstrate that long-term treatment (of at least 6&#x000a0;months) with OXN PR provides sustained analgesic efficacy for patients with moderate-to-severe cancer pain whilst maintaining improved bowel function. Increases in doses were small and there were no withdrawals due to lack of therapeutic effect indicating that pain control was maintained for the duration of the study for most subjects. The average pain scores based on the modified BPI-SF were low and stable over the 24-week OLE, indicating good analgesic efficacy during long-term treatment with OXN PR. The use of rescue medication was low and did not lead to any concern over the switching from OxyPR to OXN PR. The improvement in bowel function demonstrated with OXN PR during the double-blind phase of the study was maintained during the 24-week OLE phase, and patients who had received OxyPR during the double-blind period experienced improvement in bowel function following switch to OXN PR. Health status and QoL appeared to be maintained over the course of the OLE, with some possible improvements during the earlier part of the study.</p><p>It should be noted that data for QoL at week 24 (visit 13) included patients who had discontinued earlier in the study. Week 12 (visit 12), however, included only those data recorded at the visit. This may have contributed to any observed differences, particularly since the majority of discontinuations were due to disease progression/worsening of the condition and associated AEs.</p><p>The safety profile was as expected for this patient population, in accordance with the safety profile of opioid analgesics in this advanced cancer patient population. Although the overall AE and discontinuation rates were high, this was not unexpected considering the patient population and the duration of the study with respect to the course of cancer. The incidence of AEs in the OLE phase was comparable with that in the double-blind phase. The most frequently reported AEs were related to progression of underlying cancer disease, which is reflected in the profile of the frequently reported AEs of malignant neoplasm progression, cancer pain and nausea. The rate of treatment-related AEs (28.1&#x000a0;%) in this cancer study was in line with reported AEs in non-malignant pain populations in OLE studies of OXN PR [<xref ref-type="bibr" rid="CR28">28</xref>]. Although 59 patients (46.1&#x000a0;%) experienced SAEs, the proportion considered related to study treatment was low (only 4 patients; 3.1&#x000a0;%).</p><p>As with any clinical trial, the results of this study should be interpreted with some consideration of its limitations. Open-label extension studies are often uncontrolled and potentially biased due to patient self-selection, and further, randomized trials would better support the long-term use of OXN PR in chronic cancer pain. However, open-label studies, allow for greater patient exposure to medications, which enhances understanding of the efficacy and safety profile of the agent being investigated over a longer time period. As such, these results add to the accumulating evidence for the analgesic efficacy and improvement in bowel function and QoL associated with OXN PR, and suggest that these effects can be maintained during long-term therapy. Overall, the results reported here provide further support for the findings from the 4-week double-blind phase of this trial [<xref ref-type="bibr" rid="CR29">29</xref>] and are also in line with those seen in patients with non-malignant pain [<xref ref-type="bibr" rid="CR25">25</xref>&#x02013;<xref ref-type="bibr" rid="CR28">28</xref>].</p></sec><sec id="Sec19" sec-type="conclusion"><title>Conclusion</title><p>The findings presented here demonstrated that the benefits of OXN PR seen in the double-blind study were maintained in the 24-week OLE. For patients with moderate-to-severe cancer pain, this allows sustained analgesia whilst maintaining improved bowel function and reduced symptoms of constipation. OXN PR was not associated with any unexpected safety or tolerability issues. These findings may reassure clinicians that patients may safely remain on stable drugs for pain as their cancer progresses.</p></sec></body><back><ack><p>The authors would like to thank Medicus International for providing editorial assistance.</p><sec id="d30e1329"><title>Funding</title><p>This study, and the editorial assistance, was funded by Mundipharma Research GmbH &#x00026; Co. KG.</p></sec><sec id="d30e1334"><title>Disclosures</title><p>SA and WL have worked as consultants for Mundipharma Research; ML, HD and MH are employees of Mundipharma Research GmbH.</p></sec><sec id="d30e1339"><title>Conflict of interest</title><p>MJ and HP have no conflict of interest to declare.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serlin</surname><given-names>RC</given-names></name><name><surname>Mendoza</surname><given-names>TR</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name><name><surname>Edwards</surname><given-names>KR</given-names></name><name><surname>Cleeland</surname><given-names>CS</given-names></name></person-group><article-title>When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function</article-title><source>Pain</source><year>1995</year><volume>61</volume><issue>2</issue><fpage>277</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1016/0304-3959(94)00178-H</pub-id><pub-id pub-id-type="pmid">7659438</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ripamonti</surname><given-names>CI</given-names></name><name><surname>Santini</surname><given-names>D</given-names></name><name><surname>Maranzano</surname><given-names>E</given-names></name><name><surname>Berti</surname><given-names>M</given-names></name><name><surname>Roila</surname><given-names>F</given-names></name></person-group><article-title>Management of cancer pain: ESMO Clinical Practice Guidelines</article-title><source>Ann Oncol</source><year>2012</year><volume>23</volume><issue>Suppl 7</issue><fpage>139</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1093/annonc/mds233</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van den Beuken-van Everdingen</surname><given-names>MH</given-names></name><name><surname>de Rijke</surname><given-names>JM</given-names></name><name><surname>Kessels</surname><given-names>AG</given-names></name><name><surname>Schouten</surname><given-names>HC</given-names></name><name><surname>van Kleef</surname><given-names>M</given-names></name><name><surname>Patijn</surname><given-names>J</given-names></name></person-group><article-title>Prevalence of pain in patients with cancer: a systematic review of the past 40&#x000a0;years</article-title><source>Ann Oncol</source><year>2007</year><volume>18</volume><issue>9</issue><fpage>1437</fpage><lpage>1449</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdm056</pub-id><pub-id pub-id-type="pmid">17355955</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Breivik</surname><given-names>H</given-names></name><name><surname>Cherny</surname><given-names>N</given-names></name><name><surname>Collett</surname><given-names>B</given-names></name><name><surname>de Conno</surname><given-names>F</given-names></name><name><surname>Filbet</surname><given-names>M</given-names></name><name><surname>Foubert</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes</article-title><source>Ann Oncol</source><year>2009</year><volume>20</volume><issue>8</issue><fpage>1420</fpage><lpage>1433</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdp001</pub-id><pub-id pub-id-type="pmid">19244085</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiffen</surname><given-names>PJ</given-names></name></person-group><article-title>Evidence-based pain management and palliative care in issue one for 2005 of The Cochrane Library</article-title><source>J Pain Palliat Care Pharmacother</source><year>2005</year><volume>19</volume><issue>3</issue><fpage>65</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">16219616</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caraceni</surname><given-names>A</given-names></name><name><surname>Hanks</surname><given-names>G</given-names></name><name><surname>Kaasa</surname><given-names>S</given-names></name><name><surname>Bennett</surname><given-names>MI</given-names></name><name><surname>Brunelli</surname><given-names>C</given-names></name><name><surname>Cherny</surname><given-names>N</given-names></name><etal/></person-group><article-title>Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC</article-title><source>Lancet Oncol</source><year>2012</year><volume>13</volume><issue>2</issue><fpage>e58</fpage><lpage>e68</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(12)70040-2</pub-id><pub-id pub-id-type="pmid">22300860</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mucci-LoRusso</surname><given-names>P</given-names></name><name><surname>Berman</surname><given-names>BS</given-names></name><name><surname>Silberstein</surname><given-names>PT</given-names></name><name><surname>Citron</surname><given-names>ML</given-names></name><name><surname>Bressler</surname><given-names>L</given-names></name><name><surname>Weinstein</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: a randomized, double-blind, parallel-group study</article-title><source>Eur J Pain</source><year>1998</year><volume>2</volume><issue>3</issue><fpage>239</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.1016/S1090-3801(98)90020-9</pub-id><pub-id pub-id-type="pmid">15102384</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gimbel</surname><given-names>JS</given-names></name><name><surname>Richards</surname><given-names>P</given-names></name><name><surname>Portenoy</surname><given-names>RK</given-names></name></person-group><article-title>Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial</article-title><source>Neurology</source><year>2003</year><volume>60</volume><issue>6</issue><fpage>927</fpage><lpage>934</lpage><pub-id pub-id-type="doi">10.1212/01.WNL.0000057720.36503.2C</pub-id><pub-id pub-id-type="pmid">12654955</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coluzzi</surname><given-names>F</given-names></name><name><surname>Mattia</surname><given-names>C</given-names></name></person-group><article-title>Oxycodone. Pharmacological profile and clinical data in chronic pain management</article-title><source>Minerva Anestesiol</source><year>2005</year><volume>71</volume><issue>7&#x02013;8</issue><fpage>451</fpage><lpage>460</lpage><pub-id pub-id-type="pmid">16012419</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalso</surname><given-names>E</given-names></name></person-group><article-title>Oxycodone</article-title><source>J Pain Symptom Manage</source><year>2005</year><volume>29</volume><issue>5 Suppl</issue><fpage>S47</fpage><lpage>S56</lpage><pub-id pub-id-type="doi">10.1016/j.jpainsymman.2005.01.010</pub-id><pub-id pub-id-type="pmid">15907646</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caraceni</surname><given-names>A</given-names></name><name><surname>Pigni</surname><given-names>A</given-names></name><name><surname>Brunelli</surname><given-names>C</given-names></name></person-group><article-title>Is oral morphine still the first choice opioid for moderate to severe cancer pain? A systematic review within the European Palliative Care Research Collaborative guidelines project</article-title><source>Palliat Med</source><year>2011</year><volume>25</volume><issue>5</issue><fpage>402</fpage><lpage>409</lpage><pub-id pub-id-type="doi">10.1177/0269216310392102</pub-id><pub-id pub-id-type="pmid">21708848</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>King</surname><given-names>SJ</given-names></name><name><surname>Reid</surname><given-names>C</given-names></name><name><surname>Forbes</surname><given-names>K</given-names></name><name><surname>Hanks</surname><given-names>G</given-names></name></person-group><article-title>A systematic review of oxycodone in the management of cancer pain</article-title><source>Palliat Med</source><year>2011</year><volume>25</volume><issue>5</issue><fpage>454</fpage><lpage>470</lpage><pub-id pub-id-type="doi">10.1177/0269216311401948</pub-id><pub-id pub-id-type="pmid">21708852</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pappagallo</surname><given-names>M</given-names></name></person-group><article-title>Incidence, prevalence, and management of opioid bowel dysfunction</article-title><source>Am J Surg</source><year>2001</year><volume>182</volume><issue>5A Suppl</issue><fpage>11S</fpage><lpage>18S</lpage><pub-id pub-id-type="doi">10.1016/S0002-9610(01)00782-6</pub-id><pub-id pub-id-type="pmid">11755892</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ballantyne</surname><given-names>JC</given-names></name></person-group><article-title>Opioid analgesia: perspectives on right use and utility</article-title><source>Pain Physician</source><year>2007</year><volume>10</volume><issue>3</issue><fpage>479</fpage><lpage>491</lpage><pub-id pub-id-type="pmid">17525783</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panchal</surname><given-names>SJ</given-names></name><name><surname>Muller-Schwefe</surname><given-names>P</given-names></name><name><surname>Wurzelmann</surname><given-names>JI</given-names></name></person-group><article-title>Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden</article-title><source>Int J Clin Pract</source><year>2007</year><volume>61</volume><issue>7</issue><fpage>1181</fpage><lpage>1187</lpage><pub-id pub-id-type="doi">10.1111/j.1742-1241.2007.01415.x</pub-id><pub-id pub-id-type="pmid">17488292</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mueller-Lissner</surname><given-names>S</given-names></name></person-group><article-title>Fixed combination of oxycodone with naloxone: a new way to prevent and treat opioid-induced constipation</article-title><source>Adv Ther</source><year>2010</year><volume>27</volume><issue>9</issue><fpage>581</fpage><lpage>590</lpage><pub-id pub-id-type="doi">10.1007/s12325-010-0057-y</pub-id><pub-id pub-id-type="pmid">20714946</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mancini</surname><given-names>I</given-names></name><name><surname>Bruera</surname><given-names>E</given-names></name></person-group><article-title>Constipation in advanced cancer patients</article-title><source>Support Care Cancer</source><year>1998</year><volume>6</volume><issue>4</issue><fpage>356</fpage><lpage>364</lpage><pub-id pub-id-type="doi">10.1007/s005200050177</pub-id><pub-id pub-id-type="pmid">9695203</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurz</surname><given-names>A</given-names></name><name><surname>Sessler</surname><given-names>DI</given-names></name></person-group><article-title>Opioid-induced bowel dysfunction: pathophysiology and potential new therapies</article-title><source>Drugs</source><year>2003</year><volume>63</volume><issue>7</issue><fpage>649</fpage><lpage>671</lpage><pub-id pub-id-type="doi">10.2165/00003495-200363070-00003</pub-id><pub-id pub-id-type="pmid">12656645</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="other">Ahmedzai SH, Boland J. Constipation in people prescribed opioids. Clin Evid (Online). 2010;2010. Epub 2010/01/01.</mixed-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>YS</given-names></name><name><surname>Billings</surname><given-names>JA</given-names></name></person-group><article-title>Opioid antagonists: a review of their role in palliative care, focusing on use in opioid-related constipation</article-title><source>J Pain Symptom Manage</source><year>2002</year><volume>24</volume><issue>1</issue><fpage>71</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1016/S0885-3924(02)00424-4</pub-id><pub-id pub-id-type="pmid">12183097</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Schepper</surname><given-names>HU</given-names></name><name><surname>Cremonini</surname><given-names>F</given-names></name><name><surname>Park</surname><given-names>MI</given-names></name><name><surname>Camilleri</surname><given-names>M</given-names></name></person-group><article-title>Opioids and the gut: pharmacology and current clinical experience</article-title><source>Neurogastroenterol Motil</source><year>2004</year><volume>16</volume><issue>4</issue><fpage>383</fpage><lpage>394</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2982.2004.00513.x</pub-id><pub-id pub-id-type="pmid">15305992</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>K</given-names></name><name><surname>Hopp</surname><given-names>M</given-names></name><name><surname>Mundin</surname><given-names>G</given-names></name><name><surname>Bond</surname><given-names>S</given-names></name><name><surname>Bailey</surname><given-names>P</given-names></name><name><surname>Woodward</surname><given-names>J</given-names></name><etal/></person-group><article-title>Low absolute bioavailability of oral naloxone in healthy subjects</article-title><source>Int J Clin Pharmacol Ther</source><year>2012</year><volume>50</volume><issue>5</issue><fpage>360</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.5414/CP201646</pub-id><pub-id pub-id-type="pmid">22541841</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Culpepper-Morgan</surname><given-names>JA</given-names></name><name><surname>Inturrisi</surname><given-names>CE</given-names></name><name><surname>Portenoy</surname><given-names>RK</given-names></name><name><surname>Foley</surname><given-names>K</given-names></name><name><surname>Houde</surname><given-names>RW</given-names></name><name><surname>Marsh</surname><given-names>F</given-names></name><etal/></person-group><article-title>Treatment of opioid-induced constipation with oral naloxone: a pilot study</article-title><source>Clin Pharmacol Ther</source><year>1992</year><volume>52</volume><issue>1</issue><fpage>90</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1038/clpt.1992.106</pub-id><pub-id pub-id-type="pmid">1623695</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clemens</surname><given-names>KE</given-names></name><name><surname>Mikus</surname><given-names>G</given-names></name></person-group><article-title>Combined oral prolonged-release oxycodone and naloxone in opioid-induced bowel dysfunction: review of efficacy and safety data in the treatment of patients experiencing chronic pain</article-title><source>Expert Opin Pharmacother</source><year>2010</year><volume>11</volume><issue>2</issue><fpage>297</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.1517/14656560903483222</pub-id><pub-id pub-id-type="pmid">20030568</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simpson</surname><given-names>K</given-names></name><name><surname>Leyendecker</surname><given-names>P</given-names></name><name><surname>Hopp</surname><given-names>M</given-names></name><name><surname>Muller-Lissner</surname><given-names>S</given-names></name><name><surname>Lowenstein</surname><given-names>O</given-names></name><name><surname>De Andres</surname><given-names>J</given-names></name><etal/></person-group><article-title>Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain</article-title><source>Curr Med Res Opin</source><year>2008</year><volume>24</volume><issue>12</issue><fpage>3503</fpage><lpage>3512</lpage><pub-id pub-id-type="doi">10.1185/03007990802584454</pub-id><pub-id pub-id-type="pmid">19032132</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lowenstein</surname><given-names>O</given-names></name><name><surname>Leyendecker</surname><given-names>P</given-names></name><name><surname>Hopp</surname><given-names>M</given-names></name><name><surname>Schutter</surname><given-names>U</given-names></name><name><surname>Rogers</surname><given-names>PD</given-names></name><name><surname>Uhl</surname><given-names>R</given-names></name><etal/></person-group><article-title>Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial</article-title><source>Expert Opin Pharmacother</source><year>2009</year><volume>10</volume><issue>4</issue><fpage>531</fpage><lpage>543</lpage><pub-id pub-id-type="doi">10.1517/14656560902796798</pub-id><pub-id pub-id-type="pmid">19243306</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vondrackova</surname><given-names>D</given-names></name><name><surname>Leyendecker</surname><given-names>P</given-names></name><name><surname>Meissner</surname><given-names>W</given-names></name><name><surname>Hopp</surname><given-names>M</given-names></name><name><surname>Szombati</surname><given-names>I</given-names></name><name><surname>Hermanns</surname><given-names>K</given-names></name><etal/></person-group><article-title>Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain</article-title><source>J Pain</source><year>2008</year><volume>9</volume><issue>12</issue><fpage>1144</fpage><lpage>1154</lpage><pub-id pub-id-type="doi">10.1016/j.jpain.2008.06.014</pub-id><pub-id pub-id-type="pmid">18708300</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandner-Kiesling</surname><given-names>A</given-names></name><name><surname>Leyendecker</surname><given-names>P</given-names></name><name><surname>Hopp</surname><given-names>M</given-names></name><name><surname>Tarau</surname><given-names>L</given-names></name><name><surname>Lejcko</surname><given-names>J</given-names></name><name><surname>Meissner</surname><given-names>W</given-names></name><etal/></person-group><article-title>Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain</article-title><source>Int J Clin Pract</source><year>2010</year><volume>64</volume><issue>6</issue><fpage>763</fpage><lpage>774</lpage><pub-id pub-id-type="doi">10.1111/j.1742-1241.2010.02360.x</pub-id><pub-id pub-id-type="pmid">20370845</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmedzai</surname><given-names>SH</given-names></name><name><surname>Nauck</surname><given-names>F</given-names></name><name><surname>Bar-Sela</surname><given-names>G</given-names></name><name><surname>Bosse</surname><given-names>B</given-names></name><name><surname>Leyendecker</surname><given-names>P</given-names></name><name><surname>Hopp</surname><given-names>M</given-names></name></person-group><article-title>A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain</article-title><source>Palliat Med</source><year>2012</year><volume>26</volume><issue>1</issue><fpage>50</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1177/0269216311418869</pub-id><pub-id pub-id-type="pmid">21937568</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cleeland</surname><given-names>CS</given-names></name><name><surname>Ryan</surname><given-names>KM</given-names></name></person-group><article-title>Pain assessment: global use of the Brief Pain Inventory</article-title><source>Ann Acad Med Singapore</source><year>1994</year><volume>23</volume><issue>2</issue><fpage>129</fpage><lpage>138</lpage><pub-id pub-id-type="pmid">8080219</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rentz</surname><given-names>AM</given-names></name><name><surname>Yu</surname><given-names>R</given-names></name><name><surname>Muller-Lissner</surname><given-names>S</given-names></name><name><surname>Leyendecker</surname><given-names>P</given-names></name></person-group><article-title>Validation of the bowel function index to detect clinically meaningful changes in opioid-induced constipation</article-title><source>J Med Econ</source><year>2009</year><volume>12</volume><issue>4</issue><fpage>371</fpage><lpage>383</lpage><pub-id pub-id-type="doi">10.3111/13696990903430481</pub-id><pub-id pub-id-type="pmid">19912069</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ueberall</surname><given-names>MA</given-names></name><name><surname>Muller-Lissner</surname><given-names>S</given-names></name><name><surname>Buschmann-Kramm</surname><given-names>C</given-names></name><name><surname>Bosse</surname><given-names>B</given-names></name></person-group><article-title>The Bowel Function Index for evaluating constipation in pain patients: definition of a reference range for a non-constipated population of pain patients</article-title><source>J Int Med Res</source><year>2011</year><volume>39</volume><issue>1</issue><fpage>41</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1177/147323001103900106</pub-id><pub-id pub-id-type="pmid">21672306</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frank</surname><given-names>L</given-names></name><name><surname>Kleinman</surname><given-names>L</given-names></name><name><surname>Farup</surname><given-names>C</given-names></name><name><surname>Taylor</surname><given-names>L</given-names></name><name><surname>Miner</surname><given-names>P</given-names><suffix>Jr</suffix></name></person-group><article-title>Psychometric validation of a constipation symptom assessment questionnaire</article-title><source>Scand J Gastroenterol</source><year>1999</year><volume>34</volume><issue>9</issue><fpage>870</fpage><lpage>877</lpage><pub-id pub-id-type="doi">10.1080/003655299750025327</pub-id><pub-id pub-id-type="pmid">10522604</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aaronson</surname><given-names>NK</given-names></name><name><surname>Ahmedzai</surname><given-names>S</given-names></name><name><surname>Bergman</surname><given-names>B</given-names></name><name><surname>Bullinger</surname><given-names>M</given-names></name><name><surname>Cull</surname><given-names>A</given-names></name><name><surname>Duez</surname><given-names>NJ</given-names></name><etal/></person-group><article-title>The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology</article-title><source>J Natl Cancer Inst</source><year>1993</year><volume>85</volume><issue>5</issue><fpage>365</fpage><lpage>376</lpage><pub-id pub-id-type="doi">10.1093/jnci/85.5.365</pub-id><pub-id pub-id-type="pmid">8433390</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="other">EuroQol-a new facility for the measurement of health-related quality of life. Health Policy. 1990;16 (3):199&#x02013;208. Epub 1990/11/05.</mixed-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Handelsman</surname><given-names>L</given-names></name><name><surname>Cochrane</surname><given-names>KJ</given-names></name><name><surname>Aronson</surname><given-names>MJ</given-names></name><name><surname>Ness</surname><given-names>R</given-names></name><name><surname>Rubinstein</surname><given-names>KJ</given-names></name><name><surname>Kanof</surname><given-names>PD</given-names></name></person-group><article-title>Two new rating scales for opiate withdrawal</article-title><source>Am J Drug Alcohol Abuse</source><year>1987</year><volume>13</volume><issue>3</issue><fpage>293</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.3109/00952998709001515</pub-id><pub-id pub-id-type="pmid">3687892</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raphael</surname><given-names>J</given-names></name><name><surname>Ahmedzai</surname><given-names>S</given-names></name><name><surname>Hester</surname><given-names>J</given-names></name><name><surname>Urch</surname><given-names>C</given-names></name><name><surname>Barrie</surname><given-names>J</given-names></name><name><surname>Williams</surname><given-names>J</given-names></name><etal/></person-group><article-title>Cancer pain: part 1: pathophysiology; oncological, pharmacological, and psychological treatments: a perspective from the British pain society endorsed by the UK association of palliative medicine and the Royal College of General Practitioners</article-title><source>Pain Med</source><year>2010</year><volume>11</volume><issue>5</issue><fpage>742</fpage><lpage>764</lpage><pub-id pub-id-type="doi">10.1111/j.1526-4637.2010.00840.x</pub-id><pub-id pub-id-type="pmid">20546514</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cherny</surname><given-names>N</given-names></name><name><surname>Ripamonti</surname><given-names>C</given-names></name><name><surname>Pereira</surname><given-names>J</given-names></name><name><surname>Davis</surname><given-names>C</given-names></name><name><surname>Fallon</surname><given-names>M</given-names></name><name><surname>McQuay</surname><given-names>H</given-names></name><etal/></person-group><article-title>Strategies to manage the adverse effects of oral morphine: an evidence-based report</article-title><source>J Clin Oncol</source><year>2001</year><volume>19</volume><issue>9</issue><fpage>2542</fpage><lpage>2554</lpage><pub-id pub-id-type="pmid">11331334</pub-id></element-citation></ref></ref-list></back></article>